Jeremy Bender
CIK 1863107 · CHIEF EXECUTIVE OFFICER · last filed 2026-07-29
Jeremy Bender is a CHIEF EXECUTIVE OFFICER who has filed 59 SEC Form 4 insider transactions across 5 companies since 2022. The most recent filing, for BCAX, was dated Jul 29, 2026. Across all open-market trades the lifetime net is −$5.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $234.4K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$234.4K
5
59
-$5.43M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BCAX | Director | — | $27.73 | — | $0 | 1 | 2026-07-29 |
| AURA | Director | 30,000 | $7.70 | $231.0K | $0 | 1 | 2026-07-08 |
| Day One Biopharmaceuticals, Inc. (DAWN) Delisted | CHIEF EXECUTIVE OFFICER | 0 | $21.53 | $0 | -$5.43M | 39 | 2026-04-23 |
| MREO | Director | 12,550 | $0.27 | $3.4K | $0 | 4 | 2026-02-27 |
| Fusion Pharmaceuticals Inc. (FUSN) Delisted | Director | — | $21.55 | — | $0 | 2 | 2024-06-04 |
Recent Filings
59 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-29 | BCAX | Grant (A) | — | $0 | EDGAR |
| 2026-07-08 | AURA | Grant (A) | +30,000 | $0 | EDGAR |
| 2026-04-23 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Disp (D) | −1,799,031 | $0 | EDGAR |
| 2026-02-27 | MREO | Grant (A) | — | $0 | EDGAR |
| 2026-02-18 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Mixed | +27,478 | -$179.3K | EDGAR |
| 2026-02-17 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Notice (144) | −15,459 | -$179.3K | EDGAR |
| 2026-01-30 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-11-26 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Gift (G) | −14,450 | $0 | EDGAR |
| 2025-11-18 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Mixed | +15,800 | -$141.7K | EDGAR |
| 2025-11-17 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Notice (144) | −15,894 | -$141.7K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.